1123231-07-1Relevant articles and documents
(1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: A wingless β-catenin agonist that increases bone formation rate
Pelletier, Jeffrey C.,Lundquist IV, Joseph T.,Gilbert, Adam M.,Alon, Nipa,Bex, Frederick J.,Bhat, Bheem M.,Bursavich, Mattew G.,Coleburn, Valerie E.,Felix, Luciana A.,Green, Daniel M.,Green, Paula,Hauze, Diane B.,Kharode, Yogendra P.,Lam, Ho-Sun,Lockhead, Susan R.,Magolda, Ronald L.,Matteo, Jeanne J.,Mehlmann, John F.,Milligan, Colleen,Murrills, Richard J.,Pirrello, Jennifer,Selim, Sally,Sharp, Michael C.,Unwalla, Ray J.,Vera, Matthew D.,Wrobel, Jay E.,Yaworsky, Paul,Bodine, Peter V. N.
supporting information; experimental part, p. 6962 - 6965 (2010/08/03)
A high-throughput screening campaign to discover small molecule leads for the treatment of bone disorders concluded with the discovery of a compound with a 2-aminopyrimidine template that targeted the Wnt β-catenin cellular messaging system. Hit-tolead in
NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
-
Page/Page column 27, (2009/04/24)
The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders co